Pandemic Influenza A(H1N1)pdm09 Seroprevalence in Sweden before and after the Pandemic and the Vaccination Campaign in 2009

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Mörner, Andreas ^a   Bråve, Andreas ^a   Kling, Anna Maria ^a   Kühlmann Berenzon, Sharon ^a   Krook, Katarina ^a   Hedenskog, Mona ^a   Silhammar, Irene ^a   Ljungman, Margaretha ^a   Örtqvist, Åke ^b,c   Andersson, Sören ^a,d   Brytting, Maria ^a   Thorstensson, Rigmor ^a   Linde, Annika ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b Department of Communicable Diseases Control and Prevention ^*  (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBODY TITER; ARTICLE; CHILD; EPIDEMIC; HUMAN; INCIDENCE; INFANT; INFLUENZA A (H1N1); INFLUENZA VACCINATION; PANDEMIC INFLUENZA; PRESCHOOL CHILD; SCHOOL CHILD; SEROPREVALENCE; SWEDEN; VIRUS IMMUNITY;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MASS VACCINATION; MIDDLE AGED; PANDEMICS; SEROEPIDEMIOLOGIC STUDIES; SWEDEN; YOUNG ADULT;

EID: 84871674611     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053511     Document Type: Article

References (28)

1. Linde A, Rotzen-Ostlund M, Zweygberg-Wirgart B, Rubinova S, Brytting M, (2009) Does viral interference affect spread of influenza? Euro Surveill 14: 1-3.
2. (EMEA) TEAftEoMP (1997) Note for guidance on harmonisation of requirements for influenza vaccines. In: Unit HME, editor.
3. Brown F, Haaheim LR, Schild GC, editors (2003) Laboratory Correlates of Immunity to Influenza- A Reassessment Basel: Karger.
4. Potter CW, Oxford JS, (1979) Determinants of immunity to influenza infection in man. Br Med Bull 35: 69-75.
5. Hallander HO, Andersson M, Gustafsson L, Ljungman M, Netterlid E, (2009) Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program. APMIS 117: 912-922.
6. Kendal AP, Pereira MS, Skehel JJ (1982) Hemagglutination inhibition. In: Kendal AP, Pereira MS, Skehel JJ, editors. Concepts and procedures for laboratory-based influenza surveillance. Atlanta: Centers for Disease Control and Pan-American Health Organization. B17-35.
7. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, et al. (2003) Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 115: 63-73.
8. Hobson D, Curry RL, Beare AS, Ward-Gardner A, (1972) The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 70: 767-777.
9. Waalen K, Kilander A, Dudman SG, Krogh GH, Aune T, et al. (2010) High prevalence of antibodies to the 2009 pandemic influenza A(H1N1) virus in the Norwegian population following a major epidemic and a large vaccination campaign in autumn 2009. Euro Surveill 15.
10. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, et al. (2010) Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 375: 1100-1108.
11. Dudareva S, Schweiger B, Thamm M, Hohle M, Stark K, et al. (2011) Prevalence of antibodies to 2009 pandemic influenza A (H1N1) virus in German adult population in pre- and post-pandemic period. PLoS One 6: e21340.
12. Maltezou HC, Katerelos P, Mavrouli M, Lourida A, Routsias JG, et al. (2011) Seroepidemiological study of pandemic influenza H1N1 following the 2009-2010 wave in Greece. Vaccine 29: 6664-6669.
13. Ikonen N, Strengell M, Kinnunen L, Osterlund P, Pirhonen J, et al. (2010) High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. Euro Surveill 15.
14. (CDC) CfDCaP (2009) Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 58: 521-524.
15. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, et al. (2009) Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361: 1945-1952.
16. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1021-1025.
17. Goodwin K, Viboud C, Simonsen L, (2006) Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24: 1159-1169.
18. Remarque EJ, de Bruijn IA, Boersma WJ, Masurel N, Ligthart GJ, (1998) Altered antibody response to influenza H1N1 vaccine in healthy elderly people as determined by HI, ELISA, and neutralization assay. J Med Virol 55: 82-87.
19. Govaert TM, Sprenger MJ, Dinant GJ, Aretz K, Masurel N, et al. (1994) Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial. Vaccine 12: 1185-1189.
20. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, et al. (1994) The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 272: 1661-1665.
21. Khurana S, Verma N, Talaat KR, Karron RA, Golding H, (2012) Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. J Infect Dis 205: 610-620.
22. Verma N, Dimitrova M, Carter DM, Crevar CJ, Ross TM, et al. (2012) H1N1pdm09 infections in young and old: Evidence of higher antibody diversity and affinity for HA1 domain in elderly compared with young adults and children. J Virol.
23. Liu W, Ma MJ, Tang F, He C, Zhang XA, et al. (2012) Host immune response to A(H1N1)pdm09 vaccination and infection: a one-year prospective study on six cohorts of subjects. Vaccine 30: 4785-4789.
24. Adamson WE, McGregor EC, Kavanagh K, McMenamin J, McDonagh S, et al. (2011) Population exposure to a novel influenza A virus over three waves of infection. J Clin Virol 52: 300-303.
25. Adamson WE, McGregor EC, Kavanagh K, McMenamin J, McDonagh S, et al. (2011) Influenza A(H1N1)2009 antibody seroprevalence in Scotland following the 2010/11 influenza season. Euro Surveill 16: 19871.
26. Reinheimer C, Doerr HW, Friedrichs I, Sturmer M, Allwinn R, (2012) H1N1v at a seroepidemiological glance: is the nightmare over? Eur J Clin Microbiol Infect Dis 31: 1467-1471.
27. Garcia-Sicilia J, Gillard P, Carmona A, Tejedor JC, Aristegui J, et al. (2011) Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. Vaccine.
28. Walker WT, Faust SN, (2010) Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. Expert Rev Vaccines 9: 1385-1398.